InnoCan Pharma Corporation
INNO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -24.20% | 63.69% | 87.51% | 60.98% | 48.19% |
| Total Depreciation and Amortization | -2.70% | -8.11% | -2.78% | 6.06% | -2.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 49.95% | -25.40% | -52.16% | 19.86% | 23.42% |
| Change in Net Operating Assets | 126.23% | -85.57% | -2.97% | -107.44% | -173.55% |
| Cash from Operations | 123.97% | 78.44% | 86.70% | 59.55% | 39.70% |
| Capital Expenditure | 30.00% | -14.29% | 14.29% | 67.39% | 58.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 315.63% | 325.81% | 281.58% | 100.00% |
| Cash from Investing | 375.00% | 215.22% | 200.00% | 164.29% | 78.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 19.05% | 0.00% | 0.00% | 0.00% | -10.53% |
| Issuance of Common Stock | -94.18% | -75.17% | -79.90% | -34.79% | 64.57% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -48.35% | -31.12% | -34.22% | 32.59% | 118.34% |
| Cash from Financing | -54.82% | -39.97% | -43.89% | -7.30% | 90.43% |
| Foreign Exchange rate Adjustments | 135.29% | 220.83% | -283.78% | -722.22% | 112.06% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.23% | 13.77% | 249.80% | 205.74% | 143.19% |